ChemPartner PharmaTech Co Ltd
SZSE:300149
Intrinsic Value
ChemPartner PharmaTech Co., Ltd. engages in the research and development, production, and sale of prebiotic products. [ Read More ]
The intrinsic value of one
ChemPartner PharmaTech Co Ltd
stock under the Base Case scenario is
6.12
CNY.
Compared to the current market price of 5.31 CNY,
ChemPartner PharmaTech Co Ltd
is
Undervalued by 13%.
ChemPartner PharmaTech Co Ltd's market capitalization is 2.6B CNY.
ChemPartner PharmaTech Co Ltd stock price is 5.31 CNY.
ChemPartner PharmaTech Co Ltd stock price (5.31 CNY) is 13% less than its Intrinsic Value (6.12 CNY).
ChemPartner PharmaTech Co Ltd stock (3.37 CNY) is 37% less than its price (5.31 CNY). Open DCF Valuation
ChemPartner PharmaTech Co Ltd stock price (5.31 CNY) is 40% less than its Relative Value (8.88 CNY). Open Relative Valuation
ChemPartner PharmaTech Co Ltd has upside potential of 181% compared to the average analyst price target.
Open Wall St Estimates
ChemPartner PharmaTech Co Ltd has positive Net Debt. This means that the company has more debt (561m CNY) than cash and short-term investments (344m CNY).
ChemPartner PharmaTech Co Ltd's Revenue has dropped by 9% over the past 12 months.
ChemPartner PharmaTech Co Ltd has positive Free Cash Flow for the last twelve months.
ChemPartner PharmaTech Co Ltd has positive Gross Profit for the last twelve months.
ChemPartner PharmaTech Co Ltd's short-term assets (727m CNY) exceed its short-term liabilties (427m CNY).
ChemPartner PharmaTech Co Ltd's Revenue has been falling by 11% per year for the last 3 years.
ChemPartner PharmaTech Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 7% to -48%.
ChemPartner PharmaTech Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 4% to -35%.
ChemPartner PharmaTech Co Ltd has negative Operating Income for the last twelve months.
ChemPartner PharmaTech Co Ltd has negative Net Income for the last twelve months.
ChemPartner PharmaTech Co Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -48%.
ChemPartner PharmaTech Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -35%.
ChemPartner PharmaTech Co Ltd's long-term assets (2B CNY) exceed its long-term liabilties (998m CNY).
ChemPartner PharmaTech Co Ltd has negative three-year average ROE (Return on Equity): -7%. The company is not efficient at transforming stockholders' equity into net income.
ChemPartner PharmaTech Co Ltd has negative three-year average ROIC (Return on Invested Capital): -7%. The company is not efficient at using invested capital to generate operating income.
ChemPartner PharmaTech Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.38.
ChemPartner PharmaTech Co Ltd's Altman Z-Score is very low and is equal to 0.73.
Valuation Backtest
ChemPartner PharmaTech Co Ltd
Run backtest to discover the historical profit from buying and selling
ChemPartner PharmaTech Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
ChemPartner PharmaTech Co Ltd
Balance Sheet Decomposition
ChemPartner PharmaTech Co Ltd
| Current Assets | 727.2m |
| Cash & Short-Term Investments | 344.4m |
| Receivables | 328.1m |
| Other Current Assets | 54.6m |
| Non-Current Assets | 1.7B |
| Long-Term Investments | 279m |
| PP&E | 856.7m |
| Intangibles | 194.1m |
| Other Non-Current Assets | 402.1m |
| Current Liabilities | 426.8m |
| Accounts Payable | 53.8m |
| Accrued Liabilities | 59.4m |
| Short-Term Debt | 60m |
| Other Current Liabilities | 253.6m |
| Non-Current Liabilities | 570.9m |
| Long-Term Debt | 501.4m |
| Other Non-Current Liabilities | 69.5m |
Earnings Waterfall
ChemPartner PharmaTech Co Ltd
|
Revenue
|
1.1B
CNY
|
|
Cost of Revenue
|
-860.1m
CNY
|
|
Gross Profit
|
244.2m
CNY
|
|
Operating Expenses
|
-1.2B
CNY
|
|
Operating Income
|
-920.8m
CNY
|
|
Other Expenses
|
16m
CNY
|
|
Net Income
|
-904.8m
CNY
|
Free Cash Flow Analysis
ChemPartner PharmaTech Co Ltd
Profitability Score
Profitability Due Diligence
ChemPartner PharmaTech Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
ChemPartner PharmaTech Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ChemPartner PharmaTech Co Ltd's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
ChemPartner PharmaTech Co Ltd's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ChemPartner PharmaTech Co Ltd
According to Wall Street analysts, the average 1-year price target for
ChemPartner PharmaTech Co Ltd
is 14.94 CNY
.
Shareholder Return
Price
ChemPartner PharmaTech Co Ltd
| Average Annual Return | -6.96% |
| Standard Deviation of Annual Returns | 12.72% |
| Max Drawdown | -83% |
| Market Capitalization | 2.6B CNY |
| Shares Outstanding | 497 094 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
ChemPartner PharmaTech Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ChemPartner PharmaTech Co., Ltd. engages in the research and development, production, and sale of prebiotic products. The company is headquartered in Guangzhou, Guangdong and currently employs 2,636 full-time employees. The company went IPO on 2010-12-22. The firm's main products include fructooligosaccharides and galactooligosaccharides. The firm owns brands names of FOS and GOS. The firm's products are mainly used in nutrition and health products, dairy products, beverages, baked goods, functional candy and snack foods. The firm distributes its products mainly in domestic market, with South China as its main market.
Contact
IPO
Employees
Officers
The intrinsic value of one
ChemPartner PharmaTech Co Ltd
stock under the Base Case scenario is
6.12
CNY.
Compared to the current market price of 5.31 CNY,
ChemPartner PharmaTech Co Ltd
is
Undervalued by 13%.
You don't have any saved screeners yet
